ClinicalTrials.gg
CompletedNCT03138733Updated Oct 7, 2026Results posted

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

A Phase 3 interventional study of Ceftobiprole medocaril and Daptomycin in Staphylococcus Aureus Bacteremia, sponsored by Basilea Pharmaceutica. Completed at 60 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Basilea Pharmaceutica · Phase 3, Interventional, and Treatment

Updated Oct 7, 2026Posted results revisedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study was to compare the efficacy and safety of ceftobiprole medocaril versus a comparator in the treatment of patients with complicated Staphylococcus aureus bacteremia (SAB).

Read the detailed description

Patients were randomized 1:1 to ceftobiprole or the comparator regimen. Randomization was stratified by study site, dialysis status, and prior antibacterial treatment use within 7 days before randomization.

The three phases of the study were:

  1. Screening assessments of up to 72 hours prior to randomization
  2. Randomization and subsequent active treatment with intravenous (i.v.) study drug (ceftobiprole or daptomycin ± aztreonam).
  3. Post-treatment, comprising an end of trial (EOT) visit (within 72 hours of last study-drug administration), Day 35 (± 3 days), Day 42 (± 3 days), and a post-treatment evaluation (PTE) visit on Day 70 (± 5 days) post-randomization.
02

Conditions studied

  • Staphylococcus Aureus Bacteremia

Keywords

  • Ceftobiprole, daptomycin, Staphylococcus aureus
  • Bacteremia, bloodstream infection
03

In context

Staphylococcal Infections

304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.

This study's enrollment of 390 is above the median of 124 across 198 interventional studies indexed under Staphylococcal Infections.

Browse Staphylococcal Infections studies →

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 years of age
  • Staphylococcus aureus bacteremia (SAB), based on at least one positive blood culture obtained within the 72 h prior to randomization
  • At least one of the following signs or symptoms of bacteremia:

    1. fever (e.g.≥ 38 °C/100.4 °F measured orally)
    2. white blood cell count > 10,000 or \< 4,000 cells/µL, or > 10% immature neutrophils (bands)
    3. tachycardia (heart rate > 90 bpm)
    4. hypotension (systolic blood pressure \< 90 mmHg)
  • At least one of the following:

    1. SAB in patients undergoing chronic intermittent hemodialysis or peritoneal dialysis
    2. Persistent SAB
    3. Definite native-valve right-sided infective endocarditis by Modified Duke's Criteria
    4. Other forms of complicated SAB
    5. Osteomyelitis (including vertebral, sternal, or long-bone osteomyelitis)
    6. Epidural or cerebral abscess
  • Other inclusion criteria have been applied

Exclusion criteria

Exclusion Criteria:

  • Treatment with potentially effective (anti-staphylococcal) systemic antibacterial treatment for more than 48 h within the 7 days prior to randomization; Exception: Documented failure of bloodstream clearance
  • Bloodstream or non-bloodstream concomitant infections with Gram-negative bacteria that are known to be non-susceptible to either ceftobiprole or aztreonam
  • Left-sided infective endocarditis
  • Prosthetic cardiac valves or valve support rings, cardiac pacemakers, automatic implantable cardioverter-defibrillator, or left-ventricular assist devices
  • Community- or hospital-acquired pneumonia
  • Opportunistic infections within 30 days prior to randomization, where the underlying cause of these infections is still active
  • Requirement for continuous renal-replacement therapy
  • Women who are pregnant or nursing
  • Other exclusion criteria have been applied
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    Ceftobiprole medocaril

    Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril)

    Drug: Ceftobiprole medocaril

  • Active comparator
    Daptomycin

    Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards), with or without aztreonam

    Drug: Daptomycin

Interventions

  • Ceftobiprole 500 mg (as 667 mg ceftobiprole medocaril) as a 2 h infusion

  • Daptomycin 6 mg/kg (up to 10 mg/kg based on institutional standards) as a 0.5 h infusion, with or without aztreonam

06

What researchers measure

Primary outcomes

  1. Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit

    Comparison of overall success rates in the mITT population Overall success at PTE for the mITT population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)

    Time frame: PTE visit on Day 70 (± 5 days) post-randomization

Secondary outcomes

  1. Number of Patients With or Without Overall Success at the PTE Visit in the CE Population

    Comparison of overall success rates in the Clinical Evaluable (CE) population Overall success at PTE for the CE population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)

    Time frame: At PTE visit on Day 70 (± 5 days) post-randomization

  2. Number of Patients With Microbiological Eradication at the PTE Visit

    Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.

    Time frame: At PTE visit on Day 70 (± 5 days) post-randomization

  3. All-cause Mortality at the PTE Visit

    Comparison of all-cause mortality rates in the mITT population

    Time frame: At PTE visit on Day 70 (± 5 days) post-randomization

  4. Number of Patients With or Without New Metastatic Foci or Other Complications of SAB Developed After Day 7

    Comparison of complication rates in the mITT population defined by number of patients with development of new metastatic foci or other complications of SAB after Day 7

    Time frame: Assessment after Day 7 post-randomization through to post-treatment evaluation (PTE) visit on Day 70 (± 5 days)

  5. Time to Staphylococcus Aureus Bloodstream Clearance

    Time-to-event in the mITT Bloodstream clearance was defined as two consecutive study days with blood-culture-negative assessments for S. aureus, without any subsequent S. aureus relapse or reinfection

    Time frame: Up to 6 weeks post-randomization

  6. Number of Patients With or Without Adverse Events (AEs)

    Treatment-emergent adverse events in the safety population

    Time frame: AEs were assessed from the first dose of study drug through the post-treatment evaluation (PTE) visit on Day 70 (± 5 days)

07

Results

Posted May 6, 2023

Participant flow

Hospitalized male or female patients aged ≥ 18 years who had complicated Staphylococcus aureus bacteremia (SAB). SAB, based on ≥ 1 positive blood culture obtained within 72 h prior to randomization, with signs or symptoms of bloodstream infection

Participant flow — Overall Study
MilestoneCeftobiproleDaptomycin
Started192198
Modified itt (mitt)189198
Completed157169
Not completed3529
Withdrew: Death1718
Withdrew: Withdrawal by subject116
Withdrew: Lost to follow-up32
Withdrew: Adverse event10
Withdrew: Protocol violation13
Withdrew: Administrative or logistical reason10
Withdrew: The patient was transferred to another hospital10

Outcome measures

PrimaryNumber of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit

Comparison of overall success rates in the mITT population Overall success at PTE for the mITT population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)

Time frame:
PTE visit on Day 70 (± 5 days) post-randomization
Reported as:
Count of participants · Participants
Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit
ParticipantsCeftobiproleDaptomycin
Number of responders132136
Number of non-responders5762
Statistical analysis
  • Ceftobiprole vs Daptomycin · Adjusted proportion difference: 2.0 · 95% CI -7.1 to 11.1
SecondaryNumber of Patients With or Without Overall Success at the PTE Visit in the CE Population

Comparison of overall success rates in the Clinical Evaluable (CE) population Overall success at PTE for the CE population was defined as all of the following criteria being met (Responder): 1. Patient alive at Day 70 (± 5 days) post-randomization. 2. No new metastatic foci or complications of the SAB infection. 3. Resolution or improvement of SAB-related clinical signs and symptoms. 4. Two negative blood cultures for S. aureus (without any subsequent positive blood culture for S. aureus)

Time frame:
At PTE visit on Day 70 (± 5 days) post-randomization
Reported as:
Count of participants · Participants
Number of Patients With or Without Overall Success at the PTE Visit in the CE Population
ParticipantsCeftobiproleDaptomycin
Number of responders127130
Number of non-responders3637
Statistical analysis
  • Ceftobiprole vs Daptomycin · Adjusted proportion difference: 0.6 · 95% CI -8.3 to 9.5The two-sided 95% CI was computed using Cochran-Mantel-Haenszel (CMH) weights method adjusted for actual stratum (dialysis status and prior antibacterial treatment use)
SecondaryNumber of Patients With Microbiological Eradication at the PTE Visit

Comparison of microbiological eradication rates in the mITT population. Microbiological eradication rate was defined as a negative blood culture for S. aureus during study treatment and another negative blood culture during the follow up period up to PTE.

Time frame:
At PTE visit on Day 70 (± 5 days) post-randomization
Reported as:
Count of participants · Participants
Number of Patients With Microbiological Eradication at the PTE Visit
ParticipantsCeftobiproleDaptomycin
Number of Patients With Microbiological Eradication at the PTE Visit155153
Statistical analysis
  • Ceftobiprole vs Daptomycin · Adjusted proportion difference: 5.1 · 95% CI -2.9 to 13The two-sided 95% CI was computed using Cochran-Mantel-Haenszel (CMH) weights method adjusted for actual stratum (dialysis status and prior antibacterial treatment use)
SecondaryAll-cause Mortality at the PTE Visit

Comparison of all-cause mortality rates in the mITT population

Time frame:
At PTE visit on Day 70 (± 5 days) post-randomization
Reported as:
Count of participants · Participants
All-cause Mortality at the PTE Visit
ParticipantsCeftobiproleDaptomycin
Patients died1718
Patients alive172180
Statistical analysis
  • Ceftobiprole vs Daptomycin · Adjusted proportion difference: -0.5 · 95% CI -6.2 to 5.2The two-sided 95% CI was computed using Cochran-Mantel-Haenszel (CMH) weights method adjusted for actual stratum (dialysis status and prior antibacterial treatment use)
SecondaryNumber of Patients With or Without New Metastatic Foci or Other Complications of SAB Developed After Day 7

Comparison of complication rates in the mITT population defined by number of patients with development of new metastatic foci or other complications of SAB after Day 7

Time frame:
Assessment after Day 7 post-randomization through to post-treatment evaluation (PTE) visit on Day 70 (± 5 days)
Reported as:
Count of participants · Participants
Number of Patients With or Without New Metastatic Foci or Other Complications of SAB Developed After Day 7
ParticipantsCeftobiproleDaptomycin
Patients with development of new metastatic foci or other complications of SAB after Day 71111
Patients without development of new metastatic foci or other complications of SAB after Day 7178187
Statistical analysis
  • Ceftobiprole vs Daptomycin · Adjusted proportion difference: 0.1 · 95% CI -4.6 to 4.8The two-sided 95% CI was computed using Cochran-Mantel-Haenszel (CMH) weights method adjusted for actual stratum (dialysis status and prior antibacterial treatment use)
SecondaryTime to Staphylococcus Aureus Bloodstream Clearance

Time-to-event in the mITT Bloodstream clearance was defined as two consecutive study days with blood-culture-negative assessments for S. aureus, without any subsequent S. aureus relapse or reinfection

Time frame:
Up to 6 weeks post-randomization
Reported as:
Median · Days
Time to Staphylococcus Aureus Bloodstream Clearance
DaysCeftobiproleDaptomycin
Time to Staphylococcus Aureus Bloodstream Clearance4 (3 to 5)4 (3 to 5)
SecondaryNumber of Patients With or Without Adverse Events (AEs)

Treatment-emergent adverse events in the safety population

Time frame:
AEs were assessed from the first dose of study drug through the post-treatment evaluation (PTE) visit on Day 70 (± 5 days)
Reported as:
Count of participants · Participants
Number of Patients With or Without Adverse Events (AEs)
ParticipantsCeftobiproleDaptomycin
Any adverse events (AEs)121117
Any drug-related AE2511
Any severe AEs2938
Any study drug-related severe AEs12
Any serious adverse events (SAE)3645
Any drug-related SAEs24
Any AE leading to treatment discontinuation1818
Study drug-related AEs leading to treatment discontinuation93
Any AE leading to death1718
Study drug-related AEs leading to death00
Any AE of special interest (AESI)97
Any drug-related AESI54

Adverse events

Collected over All AEs occurring from the start of first dosing up to and including the scheduled PTE visit on Day 70 (± 5 days) were collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ceftobiprole17/191 (8.9%)36/191 (18.8%)61/191 (31.9%)
Daptomycin18/198 (9.1%)45/198 (22.7%)45/198 (22.7%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventCeftobiproleDaptomycin
Septic shockInfections and infestations4/1918/198
Multiple organ dysfunction syndromeGeneral disorders and administration site conditions4/1912/198
PneumoniaInfections and infestations3/1912/198
Cardiac failureCardiac disorders0/1913/198
COVID-19 pneumoniaInfections and infestations2/1913/198
Staphylococcal bacteraemiaInfections and infestations0/1913/198
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders2/1910/198
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/1910/198
Respiratory failureRespiratory, thoracic and mediastinal disorders2/1912/198
Gastrointestinal haemorrhageGastrointestinal disorders0/1912/198
Most frequent other events
Most frequent other events
EventCeftobiproleDaptomycin
AnaemiaBlood and lymphatic system disorders20/19124/198
NauseaGastrointestinal disorders20/1918/198
Blood potassium decreasedInvestigations17/1915/198
VomitingGastrointestinal disorders16/1914/198
Gamma-glutamyltransferase increasedInvestigations12/19115/198
DiarrhoeaGastrointestinal disorders13/1915/198

Baseline characteristics

The mITT (Intent-to-Treat population who received any dose of study medication) and who had a blood culture positive for staphylococcus aureus represented the Baseline Analysis Population. It comprised 387 out of the 390 patients in the ITT population.

Age, Continuous
Age, Continuous(years)CeftobiproleDaptomycinTotal
Mean55.5 ± 15.1856.5 ± 15.3356.0 ± 15.25
Sex: Female, Male
Sex: Female, Male(Participants)CeftobiproleDaptomycinTotal
Female128140268
Male6158119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CeftobiproleDaptomycinTotal
Hispanic or Latino141529
Not Hispanic or Latino174182356
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CeftobiproleDaptomycinTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander101
Black or African American459
White179192371
More than one race000
Unknown or Not Reported404
Region of Enrollment
Region of Enrollment(Participants)CeftobiproleDaptomycinTotal
Europe175185360
North America5510
Central America426
South America347
South Africa224
Aztreonam treatment at baseline
Aztreonam treatment at baseline(Participants)CeftobiproleDaptomycinTotal
Count of participants06262
Most frequent baseline categories of complicated SAB (Investigator-assessed)
Most frequent baseline categories of complicated SAB (Investigator-assessed)(Participants)CeftobiproleDaptomycinTotal
Skin and skin structure infection116121237
Intra-abdominal abscess262955
Chronic dialysis242549
Septic arthritis221941
Persistent SAB161632
Osteomyelitis131730
Definite right-sided endocarditis151025
08

Study locations

60 sites
  • eStudy Site - Chula Vista - PPDS
    Chula Vista, California 91911, United States
  • Triple O Medical Services Inc
    West Palm Beach, Florida 33407, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • eStudy Site - Las Vegas - PPDS
    Las Vegas, Nevada 89109, United States
  • Remington Davis Inc.
    Columbus, Ohio 43214, United States
  • Central Hospital de San Isidro Melchor Posse
    Buenos Aires, 81641, Argentina
  • Medical Institute Platense SA
    La Plata, B1900AVG, Argentina
  • British Sanatorium SA
    Rosario, S2000CVB, Argentina
  • University Multiprofile Hospital for Active Treatment "Eurohospital Plovdiv", Plovdiv, Intensive Care Clinic
    Plovdiv, 4004, Bulgaria
  • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery
    Rousse, 7002, Bulgaria
  • Multiprofile Hospital for Active Treatment "Dr. Ivan Seliminski", Sliven, Anesthesiology and Intensive Care Department
    Sliven, 8800, Bulgaria
  • University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov", Sofia, Clinic of Purulent-Septic Surgery
    Sofia, 1606, Bulgaria
  • De La Costa Clinic Ltd.
    Barranquilla, 080020, Colombia
  • JSC Rustavi Central Hospital
    Rustavi, 3700, Georgia
  • LTD High Technology Medical Center University Clinic
    Tbilisi, 0144, Georgia
  • LTD Academician G. Chapidze Emergency Cardiology Center
    Tbilisi, 0159, Georgia
  • LTD Institute of Clinical Cardiology
    Tbilisi, 0159, Georgia
  • LTD Academician Vakhtang Bochorishvili Clinic
    Tbilisi, 0160, Georgia
  • LTD Central University Clinic After Academic N. Kipshidze
    Tbilisi, 0160, Georgia
  • LTD N 5 Clinikal Hospital
    Tbilisi, 0191, Georgia
  • University Hospital Regensburg, Department of Infectious Diseases
    Regensburg, 93053, Germany
  • "LAIKO" General Hospital, 1st Department of Internal Medicine
    Athens, 11527, Greece
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • The Baruch Padeh Medical Center
    Poria Illit, 1520800, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5262000, Israel
  • Sieff Medical Center
    Safed, 1311001, Israel
  • Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • IRCCS-University Hospital San Martino-IST, Infectious Diseases Division
    Genoa, 16132, Italy
  • University of Milan-Bicocca- S.Gerardo Hospital
    Monza, 20900, Italy
  • Giuliano Isontina University Health Authority
    Trieste, 34125, Italy
  • Central Friuli University Healthcare Company
    Udine, 33100, Italy
  • Fray Antonio Alcalde Guadalajara Civil Hospital
    Guadalajara, 44280, Mexico
  • Dr. Jose Eleuterio Gonzalez Monterrey University Hospital
    Monterrey, 64460, Mexico
  • INDICASAT SMO / Santo Tomas Hospital, Investigation Department
    Panama City, 32401, Panama
  • St. Joseph Belgorod Regional Clinical Hospital
    Belgorod, 308007, Russia
  • Vinogradov Moscow Municipal Hospital, Department of Surgery #14
    Moscow, 117292, Russia
  • N.I. Pirogov City Clinical Hospital #1
    Moscow, 119049, Russia
  • Federal State Budget Institution "Central Clinical Hospital with Polyclinic" under the Presidential Executive Office of Russian Federation
    Moscow, 121359, Russia
  • L.A. Vorokhobov City Clinical Hospital #67
    Moscow, 123423, Russia
  • City Hospital #33
    Nizhny Novgorod, 603076, Russia
  • Pyatigorsk City Clinical Hospital
    Pyatigorsk, 357500, Russia
  • Regional Clinical Hospital
    Yaroslavl, 150062, Russia
  • Zvezdara University Medical Center, Clinic of Internal Diseases, Clinical Department of Nephrology and Metabolic Disorders with Dialysis "Prof. dr Vasilije Jovanovic"
    Belgrade, 11000, Serbia
  • Clinical Center Kragujevac, Center for Anesthesia and Reanimation
    Kragujevac, 34000, Serbia
  • Worthwhile Clinical Trials, Lakeview Hospital
    Benoni, 1501, South Africa
  • Mediclinic Victoria - Practice of R Moodley and MI Sarwan
    Tongaat, 4400, South Africa
  • Hospital del Mar, Department of Intensive Care
    Barcelona, 080003, Spain
  • University Hospital de Elche, Infectious Diseases Unit
    Elche, 03203, Spain
  • General University Hospital Gregorio Maranon, Infectious Diseases / Internal Medicine
    Madrid, 28007, Spain
  • University Hospital Ramon y Cajal, Department of Infectious Diseases
    Madrid, 28034, Spain
  • University Hospital Mutua de Terrassa, Unit of Infectious Diseases
    Terrassa, 08221, Spain
  • Istanbul Kartal Kosuyolu Yuksek Ihtisas Training and Research Hospital
    Istanbul, 34846, Turkey (Türkiye)
  • Ondokuz Mayis University School of Medicine, Department of Infectious Diseases
    Samsun, 55139, Turkey (Türkiye)
  • Dnipropetrovsk I.I. Mechnykov Regional Clinical Hospital
    Dnipro, 49027, Ukraine
  • Dnipropetrovsk City Multispecialty Clinical Hospital #4
    Dnipro, 49102, Ukraine
  • Ivano-Frankivsk Regional Clinical Hospital
    Ivano-Frankivsk, 76008, Ukraine
  • V.T. Zaitsev Institute of General and Emergency Surgery
    Kharkiv, 61018, Ukraine
  • Public Non-Profit Enterprise: O.O. Shalimov City Clinical Hospital #2 under Kharkiv City Council
    Kharkiv, 61037, Ukraine
  • Communal Nonprofit Enterprise "Vinnytsia Regional Clinical Hospital named after N.I. Pirogov Vinnytsia Regional Council"
    Vinnytsia, 21018, Ukraine
  • City Clinical Hospital #3
    Zaporizhzhya, 69032, Ukraine
09

References and documents

Publications

  • Hamed K, Engelhardt M, Jones ME, Saulay M, Holland TL, Seifert H, Fowler VG Jr. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol. 2020 Jan;15(1):35-48. doi: 10.2217/fmb-2019-0332. Epub 2020 Jan 10. PubMed 31918579 ↗
  • Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr; ERADICATE Study Group. Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med. 2023 Oct 12;389(15):1390-1401. doi: 10.1056/NEJMoa2300220. Epub 2023 Sep 27. PubMed 37754204 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Mar 2022, 42 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2017
First posted
May 3, 2017
StartActual
Aug 26, 2018
Primary completionActual
Mar 11, 2022
CompletionActual
Mar 11, 2022
Results first posted
May 6, 2023
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 7, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (1 Bulgaria, 1 Israel, 1 Panama, 1 Ukraine)
  • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery · Rousse, Bulgaria
  • The Baruch Padeh Medical Center · Poria Illit, Israel
  • INDICASAT SMO / Santo Tomas Hospital, Investigation Department · Panama City, Panama
  • Ivano-Frankivsk Regional Clinical Hospital · Ivano-Frankivsk, Ukraine
Show 4 removed
  • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery · Ruse, Bulgaria
  • The Baruch Padeh Medical Center · Poriyya 'Illit, Israel
  • INDICASAT SMO / Santo Tomas Hospital, Investigation Department · Panamá, Panama
  • Ivano-Frankivsk Regional Clinical Hospital · Ivano-Frankivs'k, Ukraine
Oct 7, 2026
Sponsor
Collaborators added: Biomedical Advanced Research and Development Authority; collaborators removed: Department of Health and Human Services
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Posted results revised
    4 sites added, 4 sites removed
    Show 4 added (1 Bulgaria, 1 Israel, 1 Panama, 1 Ukraine)
    • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery · Rousse, Bulgaria
    • The Baruch Padeh Medical Center · Poria Illit, Israel
    • INDICASAT SMO / Santo Tomas Hospital, Investigation Department · Panama City, Panama
    • Ivano-Frankivsk Regional Clinical Hospital · Ivano-Frankivsk, Ukraine
    Show 4 removed
    • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of General, Purulent-Septic, Pediatric and One Day Surgery · Ruse, Bulgaria
    • The Baruch Padeh Medical Center · Poriyya 'Illit, Israel
    • INDICASAT SMO / Santo Tomas Hospital, Investigation Department · Panamá, Panama
    • Ivano-Frankivsk Regional Clinical Hospital · Ivano-Frankivs'k, Ukraine
    Sponsor Collaborators added: Biomedical Advanced Research and Development Authority; collaborators removed: Department of Health and Human Services
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03138733
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 3, 2017
Start date
Aug 26, 2018
Primary completion
Mar 11, 2022
Completion
Mar 11, 2022
Results posted
May 6, 2023
Last update
Oct 7, 2026

Study contacts

Marc Engelhardt, MD
study director · Basilea Pharmaceutica

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ceftobiprole medocaril

Start the discussion